A prespecified analysis of the SURPASS-CVOT trial assessed the efficacy and safety of tirzepatide compared with dulaglutide on kidney outcomes in patients with very high-risk CKD and type 2 diabetes.
After five years on the kidney transplant list, WBZ photojournalist Jared Higginbotham is getting the most generous gift from ...
According to researcher Anne Robertson, the bladder is not considered a particularly glamorous organ, despite hosting many of ...
In India, a growing number of young adults are showing higher-than-normal uric acid levels, a condition once seen mostly in ...
Calliditas Therapeutics (Calliditas), an Asahi Kasei company, announced today that primary safety endpoints of a Phase 2a, randomized, double-blind, placebo-controlled trial of setanaxib in patients ...
Why are so many patients prescribed omeprazole for more than a month? I've been on it for years but stopped ten months ago ...
Scientists at Oregon State University have filed a patent on a design for a new magnetic resonance imaging contrast agent ...
On track to submit GraftAssureDx™ for FDA review by year-endOn track for commitment to have 20 transplant centers globally ...
The number of people living with chronic kidney disease has more than doubled in the past three decades—from 378 million in ...
When the body is dehydrated, physical performance declines. Or maybe not. Surprising research finds fit mice run more while ...
Researchers genetically engineered stomach organoids to transform them into pancreatic beta cells capable of secreting ...
The transition follows the enactment of regulations under the Public Officers Medical Scheme Fund (POMSF), which formally ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback